{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:03:11Z","timestamp":1790787791031,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>As we enter an era of precision medicine and targeted therapies in the treatment of metastatic cancer, we face new challenges for patients and providers alike as we establish clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is the fact that patients with advanced cancer may have disproportionate expectations of personal benefit when participating in clinical trials designed to generate generalizable knowledge. Patient and physician goals of treatment may not align, and reconciliation of their disparate perceptions must be addressed. However, it is particularly challenging to manage a patient's expectations when the goal of precision medicine\u2014personalized response\u2014exacerbates our inability to predict outcomes for any individual patient. The precision medicine informed consent process must therefore directly address this issue. We are challenged to honestly, clearly, and compassionately engage a patient population in an informed consent process that is responsive to their vulnerability, as well as ever-evolving indications and evidence. This era requires a continual reassessment of expectations and goals from both sides of the bed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0269","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T14:55:34Z","timestamp":1511189734000},"page":"386-388","source":"Crossref","is-referenced-by-count":25,"title":["Revisiting Expectations in an Era of Precision Oncology"],"prefix":"10.1093","volume":"23","author":[{"given":"Emily J.","family":"Marchiano","sequence":"first","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Birkeland","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Swiecicki","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA"},{"name":"Department of Internal Medicine, Division of Hematology\/Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayte","family":"Spector-Bagdady","sequence":"additional","affiliation":[{"name":"Center for Bioethics and Social Sciences in Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA"},{"name":"Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Shuman","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA"},{"name":"Center for Bioethics and Social Sciences in Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA"},{"name":"Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"2021122510440131900_onco12322-bib-0001","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122510440131900_onco12322-bib-0002","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.2010.31.8923","article-title":"American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy","volume":"29","author":"Keedy","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122510440131900_onco12322-bib-0003","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122510440131900_onco12322-bib-0004","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"key":"2021122510440131900_onco12322-bib-0005","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1371\/journal.pmed.0040324","article-title":"Clinical trials and medical care: Defining the therapeutic misconception","volume":"4","author":"Henderson","year":"2007","journal-title":"PLoS Med"},{"key":"2021122510440131900_onco12322-bib-0006","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa1204410","article-title":"Patients\u2019 expectations about effects of chemotherapy for advanced cancer","volume":"367","author":"Weeks","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122510440131900_onco12322-bib-0007","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1634\/theoncologist.10-8-636","article-title":"Informed consent for medical treatment and research: A review","volume":"10","author":"del Carmen","year":"2005","journal-title":"The Oncologist"},{"key":"2021122510440131900_onco12322-bib-0008","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.socscimed.2009.03.010","article-title":"Distinguishing research from clinical care in cancer genetics: Theoretical justifications and practical strategies","volume":"68","author":"Hallowell","year":"2009","journal-title":"Soc Sci Med"},{"key":"2021122510440131900_onco12322-bib-0009","first-page":"485","volume-title":"Handbook of Qualitative Research","author":"Altheide","year":"1994"},{"key":"2021122510440131900_onco12322-bib-0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2648.1997.t01-25-00999.x","article-title":"Sampling in qualitative research. Purposeful and theoretical sampling; merging or clear boundaries?","volume":"26","author":"Coyne","year":"1997","journal-title":"J Adv Nurs"},{"key":"2021122510440131900_onco12322-bib-0011","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122510440131900_onco12322-bib-0012","year":"2016"},{"key":"2021122510440131900_onco12322-bib-0013","article-title":"The molecular landscape of recurrent and metastatic head and neck cancers: Insights from a precision oncology sequencing platform","author":"Morris","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122510440131900_onco12322-bib-0014","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","article-title":"Whole-exome sequencing of metastatic cancer and biomarkers of treatment response","volume":"1","author":"Beltran","year":"2015","journal-title":"JAMA Oncol"},{"key":"2021122510440131900_onco12322-bib-0015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMp1603747","article-title":"Seamless oncology-drug development","volume":"374","author":"Prowell","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122510440131900_onco12322-bib-0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hast.614","article-title":"From \u201cpersonalized\u201d to \u201cprecision\u201d medicine: The ethical and social implications of rhetorical reform in genomic medicine","volume":"46","author":"Juengst","year":"2016","journal-title":"Hastings Cent Rep"},{"key":"2021122510440131900_onco12322-bib-0017","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/cncr.25201","article-title":"The culture of faith and hope: Patients\u2019 justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials","volume":"116","author":"Sulmasy","year":"2010","journal-title":"Cancer"},{"key":"2021122510440131900_onco12322-bib-0018","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1200\/JCO.2011.40.6587","article-title":"Research participants\u2019 high expectations of benefit in early-phase oncology trials: Are we asking the right question?","volume":"30","author":"Weinfurt","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122510440131900_onco12322-bib-0019","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jval.2016.04.017","article-title":"Challenges in measuring cost and value in oncology: Making it personal","volume":"19","author":"Yu","year":"2016","journal-title":"Value Health"},{"key":"2021122510440131900_onco12322-bib-0020","doi-asserted-by":"crossref","first-page":"74350","DOI":"10.18632\/oncotarget.11291","article-title":"The efficacy and potential predictive factors of PD-1\/PD-L1 blockades in epithelial carcinoma patients: A systematic review and meta analysis","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/3\/386\/41915499\/oncolo_23_3_386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/3\/386\/41915499\/oncolo_23_3_386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:46:10Z","timestamp":1640429170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/3\/386\/6439338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,11,20]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0269","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3,1]]},"published":{"date-parts":[[2017,11,20]]}}}